CEST MRI detectable liposomal hydrogels for multiparametric monitoring in the brain at 3T.

Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE

Original Publication: Wyoming, N.S.W. : Ivyspring International Publisher, 2011-

Brain/*pathology ; Glioblastoma/*therapy ; Hydrogels/*pharmacokinetics ; Liposomes/*metabolism ; Multiparametric Magnetic Resonance Imaging/*methods; Animals ; Disease Models, Animal ; Drug Delivery Systems ; Female ; Glioblastoma/diagnostic imaging ; Humans ; Hydrogels/administration & dosage ; Mice ; Mice, SCID ; Single Molecule Imaging/methods

Adjuvant treatment using local drug delivery is applied in treating glioblastoma multiforme (GBM) after tumor resection. However, there are no non-invasive imaging techniques available for tracking the compositional changes of hydrogel-based drug treatment. Methods : We developed Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST MRI) detectable and injectable liposomal hydrogel to monitor these events in vivo at 3T clinical field. Mechanical attributes of these hydrogels and their in vitro and in vivo CEST imaging properties were systematically studied. Results : The MRI detectable hydrogels were capable of generating multiparametric readouts for monitoring specific components of the hydrogel matrix simultaneously and independently. Herein, we report, for the first time, CEST contrast at -3.4 ppm provides an estimated number of liposomes and CEST contrast at 5 ppm provides an estimated amount of encapsulated drug. CEST contrast decreased by 1.57% at 5 ppm, while the contrast at -3.4 ppm remained constant over 3 d in vivo , demonstrating different release kinetics of these components from the hydrogel matrix . Furthermore, histology analysis confirmed that the CEST contrast at -3.4 ppm was associated with liposome concentrations. Conclusion : This multiparametric CEST imaging of individual compositional changes in liposomal hydrogels, formulated with clinical-grade materials at 3T and described in this study, has the potential to facilitate the refinement of adjuvant treatment for GBM.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)

Nat Rev Drug Discov. 2004 Jun;3(6):499-508. (PMID: 15173839)
Cancer Res. 2009 May 15;69(10):4167-74. (PMID: 19435897)
Biomaterials. 2018 Oct;179:199-208. (PMID: 30037456)
Magn Reson Med. 2014 May;71(5):1798-812. (PMID: 23813483)
Magn Reson Med. 2017 Feb;77(2):855-863. (PMID: 26841096)
Theranostics. 2018 Jan 13;8(4):1146-1158. (PMID: 29464005)
Biomed Mater. 2012 Apr;7(2):024101. (PMID: 22456684)
Neuro Oncol. 2012 Apr;14(4):482-90. (PMID: 22319220)
Magn Reson Med. 2012 Apr;67(4):1106-13. (PMID: 22392814)
Biomaterials. 2015 Feb;42:144-50. (PMID: 25542802)
Nat Med. 2011 Jan;17(1):130-4. (PMID: 21170048)
Biomaterials. 2003 Nov;24(24):4337-51. (PMID: 12922147)
Biomaterials. 1999 Jan;20(1):45-53. (PMID: 9916770)
Theranostics. 2017 Jan 1;7(1):228-237. (PMID: 28042330)
NMR Biomed. 2014 Oct;27(10):1239-47. (PMID: 25137521)
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96. (PMID: 25053711)
NMR Biomed. 2013 Jul;26(7):839-49. (PMID: 23784956)
J Control Release. 2016 Mar 10;225:283-93. (PMID: 26829100)
Biomaterials. 2010 Oct;31(30):7631-9. (PMID: 20656347)
Chem Rev. 2015 Oct 14;115(19):10938-66. (PMID: 26010257)
J Mater Chem B. 2016 Feb 21;4(7):1343-1353. (PMID: 32262990)
Biomacromolecules. 2011 May 9;12(5):1387-408. (PMID: 21388145)
Oncotarget. 2016 Feb 9;7(6):6369-78. (PMID: 26837220)
J Control Release. 2014 Apr 28;180:51-9. (PMID: 24548481)
Biomaterials. 2009 Sep;30(27):4695-9. (PMID: 19539367)
Eur J Cancer Clin Oncol. 1989 Dec;25(12):1795-803. (PMID: 2632261)
Expert Rev Anticancer Ther. 2013 Dec;13(12):1453-61. (PMID: 24236823)
Contrast Media Mol Imaging. 2008 Jan-Feb;3(1):38-43. (PMID: 18335476)
Neuroimage. 2013 Aug 15;77:114-24. (PMID: 23567889)
Neurosurg Rev. 2017 Jan;40(1):1-14. (PMID: 27085859)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):602-18. (PMID: 26810631)
Biomaterials. 2001 May;22(10):1113-23. (PMID: 11352091)
Patient Prefer Adherence. 2016 Nov 24;10:2397-2406. (PMID: 27920506)
Chem Soc Rev. 2012 Mar 21;41(6):2193-221. (PMID: 22116474)
Curr Oncol. 2007 Oct;14(5):189-94. (PMID: 17938702)
Biomaterials. 2017 Jul;132:16-27. (PMID: 28399459)
Magn Reson Med. 2008 Oct;60(4):803-12. (PMID: 18816830)
Neurosurg Rev. 2010 Oct;33(4):441-9. (PMID: 20706757)
Biotechnol Bioeng. 2014 Mar;111(3):441-53. (PMID: 24264728)
Prog Polym Sci. 2012 Jan;37(1):106-126. (PMID: 22125349)
J Control Release. 2017 Sep 10;261:138-146. (PMID: 28666727)
Adv Sci (Weinh). 2015 Jan 21;2(1-2):1400010. (PMID: 27980900)
Nanomedicine. 2015 Feb;11(2):401-5. (PMID: 25461289)
Cell. 2006 Aug 25;126(4):677-89. (PMID: 16923388)
Biomaterials. 2017 Apr;123:155-171. (PMID: 28171824)
Macromol Biosci. 2006 Aug 7;6(8):623-33. (PMID: 16881042)
Tissue Eng Part A. 2009 Mar;15(3):595-604. (PMID: 18991489)
J Control Release. 2016 Dec 10;243:29-42. (PMID: 27693428)
Ther Clin Risk Manag. 2007 Oct;3(5):707-15. (PMID: 18472995)
Nat Mater. 2013 Mar;12(3):268-75. (PMID: 23353626)
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101. (PMID: 24782454)
NMR Biomed. 2018 Jul;31(7):e3934. (PMID: 29806717)
NMR Biomed. 2017 Jul;30(7):. (PMID: 28272761)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Jan-Feb;6(1):111-24. (PMID: 24339357)
J Control Release. 2012 Jun 10;160(2):117-34. (PMID: 22484195)
Magn Reson Med. 2009 Jun;61(6):1441-50. (PMID: 19358232)
Colloids Surf B Biointerfaces. 2016 Aug 1;144:125-134. (PMID: 27085044)
Magn Reson Med. 2014 May;71(5):1841-53. (PMID: 23801344)
J Control Release. 2009 Sep 15;138(3):205-13. (PMID: 19442692)
J Mech Behav Biomed Mater. 2018 Jan;77:389-399. (PMID: 29017117)
Nat Clin Pract Nephrol. 2007 Dec;3(12):654-68. (PMID: 18033225)
Biomaterials. 2006 Apr;27(11):2370-9. (PMID: 16325904)
Theranostics. 2018 Feb 12;8(7):1752-1765. (PMID: 29556354)
Biomaterials. 2017 Jan;113:176-190. (PMID: 27816001)
Biomaterials. 2018 Sep;178:326-338. (PMID: 29861090)
Cancer Cell. 2005 Sep;8(3):241-54. (PMID: 16169468)
Cell Mol Life Sci. 2013 Apr;70(8):1335-56. (PMID: 22926411)
ACS Biomater Sci Eng. 2015 Apr 13;1(4):227-237. (PMID: 33435047)
Theranostics. 2017 Jan 1;7(2):285-294. (PMID: 28042334)
J Mater Sci Mater Med. 2012 Apr;23(4):999-1010. (PMID: 22354328)
Annu Rev Biomed Eng. 2008;10:391-411. (PMID: 18647117)
ACS Nano. 2017 Jan 24;11(1):797-805. (PMID: 28075559)
J Control Release. 2017 Oct 28;264:45-54. (PMID: 28830791)
Clin Pharmacokinet. 2002;41(6):403-19. (PMID: 12074689)
Pharm Res. 2009 Jul;26(7):1739-44. (PMID: 19384466)
Magn Reson Med. 2011 Apr;65(4):927-48. (PMID: 21337419)
Adv Funct Mater. 2019 Sep 5;29(36):. (PMID: 32190034)
ACS Appl Mater Interfaces. 2019 Jan 23;11(3):2782-2789. (PMID: 30584767)
Drug Discov Today. 2018 Feb;23(2):416-423. (PMID: 29074439)
ACS Nano. 2015 May 26;9(5):4686-97. (PMID: 25938172)
Mater Sci Eng C Mater Biol Appl. 2017 Dec 1;81:1-7. (PMID: 28887951)
Magn Reson Med. 2003 Mar;49(3):440-9. (PMID: 12594746)
J Magn Reson. 2000 Mar;143(1):79-87. (PMID: 10698648)
Biomater Sci. 2016 Apr;4(4):555-74. (PMID: 26818789)
Mol Imaging Biol. 2011 Feb;13(1):16-24. (PMID: 20467820)
Nat Rev Drug Discov. 2005 Feb;4(2):145-60. (PMID: 15688077)

Keywords: CEST MRI; glioblastoma; hydrogel; liposome

0 (Hydrogels)
0 (Liposomes)

Date Created: 20200225 Date Completed: 20210414 Latest Revision: 20210414

20240829

PMC7019148

10.7150/thno.40146

32089739